This study is completed in China. It is testing Deanxit, SSRI or SRNI for Somatization Disorder.
Somatic symptom disorders, Somatic symptom disordersBehavioralFrom 18 Years to 80 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Deanxit, SSRI or SRNI may be useful for adults experiencing somatic symptom disorders.
What would participation involve?
Participants may receive Deanxit, SSRI or SRNI, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in China.
Who is it mainly for?
This study appears to be mainly for adults with somatic symptom disorders.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: September 1, 2017
Recruitment status
Completed
Enrollment listed in the registry
1,863
Sponsor
RenJi Hospital
Sponsor type
Hospital / academic medical center
Study type
Behavioral
Intervention type
Medication / drug
Study phase
Not clearly listed
Locations
China
Age range
From 18 Years to 80 Years
Official registry ID
NCT03513185
Official title
The EARLY Validation and Utility of Somatic Symptom Scale CHINA for Assessing Somatic Symptom Disorder in MYOcardial Outpatients of General Hospital (EARLY-MYO-SSS-CN)
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT03513185. We help you review the study, but cannot decide medical eligibility.
Recruitment & locations
Completed
Shanghai
Registry details
Registry conditions (original wording)
Somatization Disorder
FAQ
Questions about this study
Who is behind this study?
The study sponsor is RenJi Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Deanxit, SSRI or SRNI.
Who can participate?
Listed age limits: 18 years to 80 years.
Is this study still recruiting?
The registry lists this study as completed.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
